Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers-Reference-Cited by-同舟云学术

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Published:2013-08-11 Issue:7466 Volume:501 Page:232-236
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Hatzivassiliou Georgia,Haling Jacob R.,Chen Huifen,Song Kyung,Price Steve,Heald Robert,Hewitt Joanne F. M.,Zak Mark,Peck Ariana,Orr Christine,Merchant Mark,Hoeflich Klaus P.,Chan Jocelyn,Luoh Shiuh-Ming,Anderson Daniel J.,Ludlam Mary J. C.,Wiesmann Christian,Ultsch Mark,Friedman Lori S.,Malek Shiva,Belvin Marcia

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature12441.pdf

Reference29 articles.

1. Akinleye, A., Furqan, M., Mukhi, N., Ravella, P. & Liu, D. MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol. 6, 27 (2013)

2. Blasco, R. B. et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19, 652–663 (2011)

3. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002)

4. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11–22 (2003)

5. Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355–358 (2004)

Cited by 268 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23

3. Signaling from RAS to RAF: The Molecules and Their Mechanisms;Annual Review of Biochemistry;2024-08-02

4. Trametinib, an anti-tumor drug, promotes oligodendrocytes generation and myelin formation;Acta Pharmacologica Sinica;2024-06-13

5. Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers;npj Precision Oncology;2024-05-31